Showing results (121-130 of 125) with videos related to
Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 125 results.
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|May 16, 2024
Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging studyQingyuan Zhang, Quchang Ouyang, Wei Li, et al.Breast Cancer Research and Treatment|September 23, 2021
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimensMing Shen Dai, Yin Hsun Feng, Shang Wen Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA TrialCristina Saura, Mafalda Oliveira, Yin-Hsun Feng, et al.Cancer Letters|July 12, 2025
Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in TaiwanShao-Chun Wang, Yi-Chun Shen, Mei-Ren Pan, et al.Journal of Breast Cancer|July 6, 2026
2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer ManagementJiun-I Lai, Chih-Chiang Hung, Chin-Yao Lin, et al.Pageof 13